SWM
VIR icon

SeaCrest Wealth Management’s Vir Biotechnology VIR Stock Holding History

SeaCrest Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,400
Closed -$36K – 1491
2022
Q2 		$36K Buy
+1,400
New +$32.7K ﹤0.01% 1263

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SeaCrest Wealth Management's VIR Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 1,400 shares — an estimated $36K sold.

SeaCrest Wealth Management first reported a position in VIR in Q2 2022 and held it in 1 quarter. The position peaked at $36K in Q2 2022. 220 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

  • SeaCrest Wealth Management reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,400 Vir Biotechnology shares in Q3 2022, an estimated $36K.
  • SeaCrest Wealth Management first reported a position in Vir Biotechnology in Q2 2022 and held it in 1 quarter.
  • SeaCrest Wealth Management's Vir Biotechnology position peaked at $36K in Q2 2022.
  • 220 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.